Dianthus Therapeutics (NASDAQ:DNTH) Shares Gap Down to $27.88

Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) gapped down prior to trading on Wednesday . The stock had previously closed at $27.88, but opened at $27.18. Dianthus Therapeutics shares last traded at $27.79, with a volume of 13,869 shares.

Analyst Upgrades and Downgrades

A number of brokerages have commented on DNTH. Wedbush reduced their target price on Dianthus Therapeutics from $38.00 to $36.00 and set an "outperform" rating for the company in a report on Friday, August 9th. Baird R W upgraded Dianthus Therapeutics to a "strong-buy" rating in a report on Friday, July 26th. Cantor Fitzgerald began coverage on shares of Dianthus Therapeutics in a report on Thursday, June 27th. They set an "overweight" rating for the company. Robert W. Baird initiated coverage on shares of Dianthus Therapeutics in a research report on Friday, July 26th. They issued an "outperform" rating and a $58.00 target price for the company. Finally, Lifesci Capital upgraded shares of Dianthus Therapeutics to a "strong-buy" rating in a research report on Tuesday, June 11th. Eight analysts have rated the stock with a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat, Dianthus Therapeutics has a consensus rating of "Buy" and an average target price of $44.71.

Dianthus Therapeutics Price Performance

The company has a market capitalization of $821.19 million, a PE ratio of -4.80 and a beta of 1.85. The business's 50 day simple moving average is $27.90 and its 200 day simple moving average is $26.20.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.51) EPS for the quarter, missing the consensus estimate of ($0.50) by ($0.01). The firm had revenue of $1.86 million for the quarter, compared to analysts' expectations of $0.63 million. Dianthus Therapeutics had a negative net margin of 1,376.42% and a negative return on equity of 21.03%. As a group, analysts anticipate that Dianthus Therapeutics, Inc. will post -2.32 EPS for the current year.

Hedge Funds Weigh In On Dianthus Therapeutics

A number of hedge funds have recently modified their holdings of DNTH. SG Americas Securities LLC purchased a new stake in Dianthus Therapeutics in the 2nd quarter valued at about $112,000. The Manufacturers Life Insurance Company purchased a new stake in shares of Dianthus Therapeutics in the 2nd quarter valued at approximately $236,000. WINTON GROUP Ltd purchased a new stake in shares of Dianthus Therapeutics in the 2nd quarter valued at approximately $265,000. Point72 DIFC Ltd acquired a new position in shares of Dianthus Therapeutics in the 2nd quarter worth approximately $334,000. Finally, Virtu Financial LLC purchased a new position in shares of Dianthus Therapeutics during the 1st quarter worth approximately $390,000. 47.53% of the stock is currently owned by hedge funds and other institutional investors.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.